FMP

FMP

Enter

BCRX - BioCryst Pharmaceuti...

Financial Summary of BioCryst Pharmaceuticals, Inc.(BCRX), BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule m

photo-url-https://financialmodelingprep.com/image-stock/BCRX.png

BioCryst Pharmaceuticals, Inc.

BCRX

NASDAQ

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

4.66 USD

-0.015 (-0.322%)

About

ceo

Mr. Jon P. Stonehouse

sector

Healthcare

industry

Biotechnology

website

https://www.biocryst.com

exchange

NASDAQ

Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, w...

CIK

0000882796

ISIN

US09058V1035

CUSIP

09058V103

Address

4505 Emperor Boulevard

Phone

919 859 1302

Country

US

Employee

536

IPO Date

Mar 4, 1994

Summary

CIK

0000882796

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

09058V103

ISIN

US09058V1035

Country

US

Price

4.66

Beta

1.93

Volume Avg.

3.08M

Market Cap

959.63M

Shares

-

52-Week

4.45-9.07

DCF

15.51

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-3.94

P/B

-

Website

https://www.biocryst.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest BCRX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep